Innoviva Acquires Entasis Therapeutics

Innoviva Acquires La Jolla Pharmaceutical Company

July 11, 2022

Pharmaceuticals

Innoviva, Inc. completed a cash tender offer to acquire La Jolla Pharmaceutical Company for $6.23 per share, valuing the deal at an implied enterprise value of approximately $149 million. The acquisition adds La Jolla's marketed infectious disease and hospital products (GIAPREZA and XERAVA) to Innoviva's healthcare portfolio to expand its commercial footprint in anti-infectives and hospital therapeutics.

Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics

August 31, 2020

Biotechnology

Ionis Pharmaceuticals agreed to acquire the approximately 24% of Akcea Therapeutics it does not already own for $18.15 per share in cash, implying a fully diluted transaction value of about $500 million. The deal will be executed via a tender offer followed by a second-step merger, and Ionis expects to complete the transaction in Q4 2020 to consolidate Akcea's pipeline, commercial products and cash while realizing cost synergies.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.

Innova Therapeutics Acquires Enci Therapeutics

November 27, 2025

Biotechnology

Innova Therapeutics has completed the acquisition of Enci Therapeutics, adding Enci’s lead oncology program, IVT-8086, a first-in-class humanized monoclonal antibody targeting SFRP2, to its development pipeline. Financial terms were not disclosed; Innova said the program and associated IP (patents through at least 2042) will support development across multiple solid and hematologic cancers and a companion diagnostic is in development.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

Altavant Sciences Acquires Onspira Therapeutics

January 8, 2020

Biotechnology

Altavant Sciences has acquired Onspira Therapeutics, adding OSP-101 — an inhaled interleukin-1 receptor antagonist with orphan drug designation for bronchiolitis obliterans syndrome (BOS) — to its rare respiratory disease pipeline. The deal closed with upfront and milestone payments to Onspira's shareholders and expands Altavant's capabilities in pulmonary transplant-related therapeutics.